Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
BioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.
The European Commission has reserved 300 million doses from Sanofi SA/GSK plcs adjuvanted recombinant COVID-19 vaccine.
Roche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.
Italian start-up Enthera Pharmaceuticals has raised 28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
Swiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.
In a Public England Health study, Siemens Healthineers COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.
After leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).
Leiden-based coagulant developer VarmX NV has closed a 32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.